Calissendorff Swarting represented Aprea AB in the largest financing of a private equity Swedish Life Science company in a decade

Calissendorff Swarting represented Aprea AB, a subsidiary of Karolinska Development AB, in a SEK 437 million financing.

The financing is the largest private financing to date by any of Karolinska Development's companies portfolio, and more broadly by any Swedish private Life Sciences company in the last decade. The investors consisted of Life Sciences investors Versant Ventures and 5AM (US), Sectoral Asset Management (Canada) and HealthCap (Sweden). Karolinska Development participated via the conversion of outstanding loans.